Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer
ConclusionOur study identifiedPIK3CA mutations as a poor prognostic factor, and our meta-analysis identifiedPIK3CA mutations as predictive of decreased response to anti-EGFR therapy in patients with mCRC. (Source: Targeted Oncology)
Source: Targeted Oncology - June 29, 2022 Category: Cancer & Oncology Source Type: research

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
ConclusionsIn our real-world cohort, most patients received nivolumab as second-line treatment. Outcomes of single drugs are superimposable with those in the published literature. Both the sequences of nivolumab and cabozantinib appear to be viable, effective strategies from an OS and cost-effective perspective. (Source: Targeted Oncology)
Source: Targeted Oncology - June 25, 2022 Category: Cancer & Oncology Source Type: research

Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
ConclusionsOur findings show that PK simulations of early clinical data together with ex vivo cytotoxicity estimates can inform the identification of a bispecific antibody ’s therapeutic range.Clinical Trial RegistrationNCT03145181, date of registration: May 9, 2017. (Source: Targeted Oncology)
Source: Targeted Oncology - June 24, 2022 Category: Cancer & Oncology Source Type: research

Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer
Conclusion and RelevanceAmong patients with advanced/metastatic TRK fusion cancer, medical oncologists reported testing forNTRK fusions at diagnosis or prior to 1L. Future research should elucidate why fewer than half of oncologists surveyed (46%) would not use TRKis afterNTRK+ status confirmation, assess clinical practices amongNTRK+ patients, and characterize treatment patterns and clinical outcomes in real-world settings. (Source: Targeted Oncology)
Source: Targeted Oncology - June 18, 2022 Category: Cancer & Oncology Source Type: research

Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study
ConclusionsThe safety profile of cobimetinib in pediatrics was similar to that reported in adults. Clinical activity was observed in LGG patients with known/suspected MAPK pathway activation. Cobimetinib combination regimens may be required to improve response rates in this pediatric population.Clinical Trial RegistrationClinicalTrials.gov NCT02639546, registered December 24, 2015. (Source: Targeted Oncology)
Source: Targeted Oncology - June 17, 2022 Category: Cancer & Oncology Source Type: research

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC
AbstractOsimertinib (TAGRISSO®) is an orally administered, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is approved for the adjuvant treatment of adults with completely resected, stage IB –IIIA,EGFR sensitizing mutation (exon 19 deletion or exon 21 [L858R] substitution)-positive non-small cell lung cancer (NSCLC). In the pivotal ADAURA trial in adults with completely resected, early-stage,EGFR mutation-positive (EGFRm+) NSCLC, osimertinib adjuvant therapy significantly prolonged disease-free survival (DFS) compared with placebo in the overall population of patients with stage I...
Source: Targeted Oncology - June 17, 2022 Category: Cancer & Oncology Source Type: research

Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
ConclusionsSerial molecular profiling identifies early therapy-induced genomic alterations, which may guide future selection of targeted therapies in breast cancer patients who progress after standard chemotherapy.Clinical trial registrationClinicalTrials.gov: NCT02790580 (first posted June 6, 2016). (Source: Targeted Oncology)
Source: Targeted Oncology - June 14, 2022 Category: Cancer & Oncology Source Type: research

Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor
ConclusionsBased on these results, CTC PD-L1 and IRF-1 expression is of interest in identifying ICI resistance and warrants further study. (Source: Targeted Oncology)
Source: Targeted Oncology - June 13, 2022 Category: Cancer & Oncology Source Type: research

When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents
AbstractEarly clinical trials investigating antiPD(L)-1 agents rarely reached  a maximum tolerated dose (MTD), and efficacy signals were observed even at the lowest dose levels. Most extended treatment intervals investigated indicated that these drugs do not follow a direct dose-toxicity or dose-efficacy relationship. Within this context and considering the high cost of an tiPD(L)-1 agents, there is a significant debate on whether lower doses or the administration of such agents at an extended interval should be prospectively evaluated in already-approved agents, or at least be considered in novel combination trials inv...
Source: Targeted Oncology - June 10, 2022 Category: Cancer & Oncology Source Type: research

A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study
ConclusionsIn the MOBILITY3 study (NCT02506517), afatinib demonstrated modest activity in tumors that possessEGFR andERBB2 aberrations. Clinical benefit seen in all 3 salivary gland cancers supports the growing evidence for the utility of HER-targeted therapies in the treatment of this specific tumor type. (Source: Targeted Oncology)
Source: Targeted Oncology - May 30, 2022 Category: Cancer & Oncology Source Type: research

Antibody –Drug Conjugates in Uro-Oncology
AbstractCurrently available treatment options for patients with refractory metastatic prostate, bladder, or kidney cancers are limited with the prognosis remaining poor. Advances in the pathobiology of tumors has led to the discovery of cancer antigens that may be used as the target for cancer treatment. Antibody –drug conjugates (ADCs) are a relatively new concept in cancer treatment that broaden therapeutic landscape. ADCs are examples of a ‘drug delivery into the tumor’ system composed of an antigen-directed antibody linked to a cytotoxic drug that may release cytotoxic components after binding to t he antigen loc...
Source: Targeted Oncology - May 14, 2022 Category: Cancer & Oncology Source Type: research

Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy
ConclusionsPrimary tumor site is a clinically useful biomarker to predict survival in patients with metastatic colorectal cancer treated with first-line chemotherapy. Moreover, the prognostic or predictive value of several gene alterations by primary tumor site should be considered in clinical practice. (Source: Targeted Oncology)
Source: Targeted Oncology - May 7, 2022 Category: Cancer & Oncology Source Type: research

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
The article “Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer. (Source: Targeted Oncology)
Source: Targeted Oncology - May 5, 2022 Category: Cancer & Oncology Source Type: research

Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era
ConclusionsThe present multi-institution real-world data showed the improved outcome of previously untreated patients with metastatic renal cell carcinoma in the ICI era group compared with that in the molecular-targeted therapy era group. These findings strongly encourage the use of ICI-based treatment for patients with metastatic renal cell carcinoma in the real-world setting. Further studies with extended follow-up periods are needed to confirm our findings. (Source: Targeted Oncology)
Source: Targeted Oncology - April 23, 2022 Category: Cancer & Oncology Source Type: research

The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
ConclusionsOur research demonstrates that there was no strong evidence showing that patients taking osimertinib as first-line treatment experienced longer median progression-free survival and overall survival than patients treated with afatinib. However, there was a statistical significance revealing that osimertinib provided better median progression-free survival than afatinib in patients with brain metastasis at baseline. (Source: Targeted Oncology)
Source: Targeted Oncology - April 23, 2022 Category: Cancer & Oncology Source Type: research